Showing 2561-2570 of 3315 results for "".
- Neurolenses Demonstrate Headache Relief in New Studyhttps://modernod.com/news/neurolenses-demonstrate-headache-relief-in-new-study/2482145/Neurolens announced results of a company-sponsored study evaluating the impact of Neurolens prescription lenses on individuals with headaches. The six-item Headache Impact Test (H
- Study: Blindness from Some Inherited Eye Diseases May be Caused by Gut Bacteriahttps://modernod.com/news/study-blindness-from-some-inherited-eye-diseases-may-be-caused-by-gut-bacteria/2482140/Sight loss in certain inherited eye diseases may be caused by gut bacteria, and is potentially treatable by antimicrobials, according to a new study in mice co-led by a University College London (UCL) and Moorf
- Glaukos' iDose TR Now Commercially Availablehttps://modernod.com/news/glaukos-idose-tr-now-commercially-available/2482139/Glaukos' iDose TR (travoprost intracameral implant 75 mcg), which uses Celanese’s VitalDose EVA (Ethylene Vinyl Acetate) to provide sustained drug release for the treatment of glaucoma, is now commerically available, according to Celanese. The iDo
- Ace Vision Group Names Val Kolesnitchenko, MD, as Chief Scientific Officerhttps://modernod.com/news/ace-vision-group-names-val-kolesnitchenko-md-as-chief-scientific-officer/2482095/Ace Vision Group announced that it has named Val Kolesnitchenko, MD, as Chief Scientific Officer. Dr. Kolesnitchenko has served in leadership roles for three decades in clinical ophthalmology practice and industry. Most recently, he held the position of Executive Director of Global
- EuroEyes Group Wins SMILE Refractive Laser Eye Surgery Awardhttps://modernod.com/news/euroeyes-group-wins-smile-refractive-laser-eye-surgery-award/2482087/LEC London announced that its parent company EuroEyes Clinic Group, has won the SMILE Laser Operations Award for conducting the highest number of SMILE (Small Incision Lenticule Extraction) laser operations in Europe last year (2023). EuroEyes performed a total of 9,550 SMILE operations
- Mireca Medicines Awarded Nearly $1 Million from the Foundation Fighting Blindness to Develop Treatments for IRDshttps://modernod.com/news/mireca-medicines-awarded-nearly-1-million-from-the-foundation-fighting-blindness-to-develop-treatments-for-inherited-retinal-diseases/2482085/Mireca Medicines announced it has received a $989,000 'Translational Research Acceleration Program Award' from Foundation Fighting Blindness that will permit the company to further advance the preclinical development of its lead product MM238. In a news
- Sydnexis Appoints Erin Horn as Vice President, Head of Market Accesshttps://modernod.com/news/sydnexis-names-erin-horn-as-vice-president-head-of-market-access/2482071/Sydnexis has announced the appointment of Erin Horn as Vice President, Head of Market Access. Ms. Horn will lead Sydnexis’ market access, pricing, contracting, and go-to-market strategies. With 25 years of industry experience, Ms. Horn has a track record of commercial success
- Aviceda Enrolls First Patient in Phase 2 GLYCO Clinical Trial Evaluating AVD-104 for the Treatment of DMEhttps://modernod.com/news/aviceda-enrolls-first-patient-in-phase-2-glyco-clinical-trial-evaluating-avd-104-for-the-treatment-of-dme/2482058/Aviceda Therapeutics announced that it has enrolled the first patient in the GLYCO phase 2 US clinical trial evaluating its lead ophthalmic candidate AVD-104 for the management of diabetic macular edema (DME). AVD-104 is an engineered glycan (sialic acid) nanoparticle that reduces inflammati
- IntRIS Hosts ARCR Macular 2024 Meeting and Presents Interview With FDA’s Dr. Wiley Chambershttps://modernod.com/news/intris-hosts-arcr-macular-2024-meeting-and-presents-interview-with-fdas-dr-wiley-chambers/2482057/The International Retinal Imaging Society (IntRIS) hosted the Atlantic Coast Retina Club (ACRC) Macula 2024, led by K. Bailey Freund, MD. According IntRIS, the ACRC meeting format includes rapid-fire single-case presentations, engaging discussions, and conferences covering diverse retin
- Claris Bio Advances Corneal Healing Product Candidate; Secures New Fundinghttps://modernod.com/news/claris-bio-developer-of-corneal-healing-product-candidate-names-new-investor/2482042/Claris Bio unveiled the company and its lead program with a total of $57 million invested. Claris, initially funded in 2020, is developing recombinant human variant hepatocyte growth factor, dHGF, to accelerate and improve the quality of corneal healing in patients with corneal eye dise